Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 7:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 793–816 of 924 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psoriasis Clear all
Not listed No phase listed Observational Accepts healthy volunteers

Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis

NCT01122095
View directory record Official record
Conditions
Psoriasis, Obesity, Cardiovascular Risk, Inflammation
Interventions
Not listed
Lead sponsor
University of California, San Diego
Other
Eligibility
Up to 18 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 31, 2010 · Synced Oct 25, 2026, 7:55 AM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy, Safety and Effect on Radiographic Progression of Brodalumab in Subjects With Psoriatic Arthritis

NCT02029495
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
210 mg brodalumab, 140 mg brodalumab, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
43
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 25, 2026, 7:55 AM EDT
Completed Phase 3 Interventional

Treatment of Psoriasis Using Acitretin in HIV-Positive Patients

NCT00002143
View directory record Official record
Conditions
HIV Infections, Psoriasis
Interventions
Acitretin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 7:55 AM EDT
Completed Phase 2 Interventional Results available

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

NCT00820950
View directory record Official record
Conditions
Psoriasis
Interventions
Ruxolitinib phosphate cream, Dovonex® calcipotriene 0.005%, Diprolene® AF betamethasone dipropionate 0.05% cream., Placebo cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Vallejo, California • Boston, Massachusetts • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Oct 25, 2026, 7:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

NCT01406938
View directory record Official record
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
AIN457 150mg, AIN457 300mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
967 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Fresno, California • Pasadena, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 25, 2026, 7:55 AM EDT
Completed Phase 4 Interventional

Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis

NCT00437255
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Clobetasol Propionate, 0.05%, Calcipotriene and betamethasone dipropionate ointment
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Fridley, Minnesota • Austin, Texas • Bryan, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 25, 2026, 7:55 AM EDT
Recruiting Not applicable Interventional

A Study to Evaluate the Impact of a Magnolia Officinalis Dietary Supplement on Immune Biomarkers in Subjects With Psoriasis

NCT07471048
View directory record Official record
Conditions
Psoriasis
Interventions
Oral supplement containing 200mg Magnolia officinalis bark extract, Placebo
Dietary Supplement
Lead sponsor
Sirt3 LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 25, 2026, 7:55 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

NCT06425549
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
bimekizumab, ustekinumab, placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
6 Years to 17 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
7
States / cities
Fountain Valley, California • Los Angeles, California • Northridge, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 25, 2026, 7:55 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Iontophoresis in Psoriasis

NCT03979664
View directory record Official record
Conditions
Psoriasis, Psoriasis Vulgaris, Skin Diseases
Interventions
Activapatch intellidose 2.5 using active Iontophoresis, Activapatch intellidose 2.5 using inactive Iontophoresis, Dexamethasone
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2021 · Synced Oct 25, 2026, 7:55 AM EDT
Completed Phase 4 Interventional Results available

Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy

NCT03000309
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Apremilast
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 25, 2026, 7:55 AM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

NCT01610596
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Halobetasol Propionate Lotion 0.05%, Placebo
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
San Diego, California • Fridley, Minnesota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 13, 2016 · Synced Oct 25, 2026, 7:55 AM EDT
Completed Not applicable Interventional

A Study of Retrovir in the Treatment of Psoriasis in HIV-Positive Patients

NCT00002286
View directory record Official record
Conditions
HIV Infections, Psoriasis
Interventions
Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Research Triangle Park, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 25, 2026, 7:55 AM EDT
Recruiting Phase 4 Interventional

ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.

NCT04347473
View directory record Official record
Conditions
Psoriasis
Interventions
Ilumya Injectable Product
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 25, 2026, 7:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis

NCT01752634
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab (AIN457), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
21
States / cities
Peoria, Arizona • Aventura, Florida • Palm Harbor, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 25, 2026, 7:55 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy

NCT04115839
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Filgotinib, Placebo to match filgotinib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
22
States / cities
Covina, California • DeBary, Florida • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 25, 2026, 7:55 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of MM-093 in Patients With Chronic Plaque Psoriasis

NCT00147329
View directory record Official record
Conditions
Psoriasis
Interventions
MM-093
Drug
Lead sponsor
Merrimack Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Dallas, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 23, 2007 · Synced Oct 25, 2026, 7:55 AM EDT
Completed Phase 1 Interventional

A Study of RO5310074 in Patients With Psoriatic Arthritis

NCT01199809
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Placebo, RO5310074
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Anniston, Alabama • Los Angeles, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 25, 2026, 7:55 AM EDT
Completed Phase 2 Interventional

Study of MEDI-507 Administered by Intravenous Infusion to Adults With Plaque Psoriasis

NCT00192452
View directory record Official record
Conditions
Psoriasis
Interventions
MEDI-507
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
3
States / cities
Phoenix, Arizona • Winston-Salem, North Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Oct 25, 2006 · Synced Oct 25, 2026, 7:55 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 Injections

NCT07232004
View directory record Official record
Conditions
Healthy Volunteer, Psoriasis
Interventions
ABBV-547, ABBV-547 Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 70 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Bryant, Arkansas • Anaheim, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 7:55 AM EDT
Terminated Phase 2 Interventional Results available

AGN-242428 in the Treatment of Plaque Psoriasis

NCT03339999
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
AGN-242428, Placebo
Drug
Lead sponsor
Vitae Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 25, 2026, 7:55 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

NCT06878404
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Icotrokinra, Placebo, Active reference comparator
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Jonesboro, Arkansas • DeBary, Florida • Plantation, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 25, 2026, 7:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis

NCT01172938
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Apremilast 20mg, Apremilast 30mg, Placebo + 20 mg Apremilast, Placebo + 30 mg Apremilast
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 25, 2026, 7:55 AM EDT
Completed Phase 4 Interventional

Open Label Study of the Effects of Secukinumab on Nail Psoriasis and Non-Invasive Measures of Enthesitis (Phase IV)

NCT04535999
View directory record Official record
Conditions
Psoriasis
Interventions
Secukinumab Auto-Injector
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 25, 2026, 7:55 AM EDT
Terminated Phase 2 Interventional

Study of BMS-587101 in Patients With Moderate to Severe Psoriasis

NCT00162253
View directory record Official record
Conditions
Psoriasis, Moderate to Severe
Interventions
BMS 587101
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
16
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 25, 2026, 7:55 AM EDT